Awardee OrganizationBOSTON UNIVERSITY MEDICAL CAMPUS
Description
Abstract Text
Project Summary: Sepsis remains a leading cause of morbidity and mortality with almost 50 million cases per
year worldwide. In the absence of FDA-approved drugs, there is a high demand for better insights into the host-
microbe interactions that define the molecular pathogenesis of sepsis. Polyphosphates are linear polymers of
inorganic phosphate (Pi) residues that are present in all living organisms. The metabolism of bacteria
accumulates long-chains of polyphosphates (Pi: n≥1,000) in contrast to the short-chain polyphosphates (Pi:
n<100) typically found in mammalian cells. The biologic effects are dependent on chain length. Emerging data
suggest that short-chain polyphosphates modulate blood coagulation and inflammation, while the role of long-
chain, bacteria-derived, polyphosphates in sepsis is an understudied research field. Our preliminary work
suggests that neutralization of polyphosphates or bacterial polyphosphate deficiency improves survival of
peritoneal sepsis induced by cecum ligation and puncture (CLP) in mice. In sterile macrophage cultures, long-
chain polyphosphates modulate LPS/TLR4-induced macrophage polarization, iNOS expression and immuno-
metabolism. Here, we propose to test the central hypothesis that bacterial polyphosphates are lethal metabolites
in sepsis because of their detrimental interference with the innate host response to infection. To shed light into
the biological activities of polyphosphates, we propose to address 3 specific aims: (1) To study the effects of
polyphosphate neutralization, we will use a recombinant exopolyphosphatase (PPX) protein and characterize its
activities on the host response to polymicrobial CLP sepsis. A single-cell proteogenomics approach (CITE-Seq)
will aim to capture the heterogeneity/polarization of invading professional phagocytes as a function of
polyphosphates. The polyphosphates will be measured in sepsis samples of mice and humans. (2) To
characterize the direct interference of polyphosphates with the functions of cultured macrophages, we will
combine bacterial TLR agonists with synthetic polyphosphates of different chain length. It will be studied if
polyphosphates curb STAT/IRF signaling pathways for modulating iNOS, L-arginase, cytokines/chemokines,
and metabolic reprogramming (OXPHOS, glycolysis). In addition, affinity purification combined with label-free
proteomics will aim for the identification of novel polyphosphate targeted proteins in macrophages; to better
understand the mechanisms how polyphosphates interfere with phagocyte responses in sepsis. (3) In gnotobiotic
mice, monocolonized with a polyphosphate-deficient E. coli mutant (Δppk), we will investigate how bacteria-
derived polyphosphates shape innate immunity before and after monomicrobial CLP sepsis. Peritoneal and
intestinal mucosal macrophages will be characterized and compared for their functions, transcriptome plasticity
and immuno-metabolic phenotypes. This research project will provide novel insights into the unexplored activities
of bacterial polyphosphates within the networks of host-pathogen interactions of sepsis and may ultimately
advance strategies for therapeutic reversal of maladaptive inflammatory milieus.
Public Health Relevance Statement
Project Narrative
Polyphosphates are an understudied class of inorganic polymers, which are accumulated by
bacteria as long linear chains of orthophosphate residues. Here, we hypothesize that
bacterial polyphosphates interfere with a protective host immune response and mediate
harmful outcomes of septic peritonitis after cecum ligation and puncture. The proposed
studies aim for new insights into the pathogenesis of polyphosphate-dependent host-microbe
interactions in the peritoneal/mucosal microenvironment and will help to better understand
the systemic injury response to bacterial sepsis.
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
604483045
UEI
FBYMGMHW4X95
Project Start Date
22-February-2021
Project End Date
31-January-2026
Budget Start Date
01-February-2024
Budget End Date
31-January-2026
Project Funding Information for 2024
Total Funding
$537,125
Direct Costs
$325,530
Indirect Costs
$211,595
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Allergy and Infectious Diseases
$537,125
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01AI153613-04
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01AI153613-04
Patents
No Patents information available for 5R01AI153613-04
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01AI153613-04
Clinical Studies
No Clinical Studies information available for 5R01AI153613-04
News and More
Related News Releases
No news release information available for 5R01AI153613-04
History
No Historical information available for 5R01AI153613-04
Similar Projects
No Similar Projects information available for 5R01AI153613-04